CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
| Project Number | PC0007-000 |
|---|---|
| Brand Name | Afinitor |
| Generic Name | Everolimus |
| Strength | 2.5 mg, 5 mg and 10 mg |
| Tumour Type | Gastrointestinal |
| Indication | Pancreatic neuroendocrine tumours |
| Funding Request | Patients with well- or moderately differentiated neuroendocrine tumours of pancreatic origin (pNET) in patients with unresectable, locally advanced or metastatic disease. |
| Review Status | Complete |
| Pre Noc Submission | No |
| NOC Date | February 2, 2012 |
| Manufacturer | Novartis Pharmaceuticals Canada Inc. |
| Sponsor | Novartis Pharmaceuticals Canada Inc. |
| Submission Date | February 27, 2012 |
| Submission Deemed Complete | March 5, 2012 |
| Submission Type | Initial |
| Prioritization Requested | Not Requested |
| Stakeholder Input Deadline ‡ | March 12, 2012 |
| Check-point meeting | April 18, 2012 |
| pERC Meeting | June 21, 2012 |
| Initial Recommendation Issued | July 6, 2012 |
| Feedback Deadline ‡ | July 20, 2012 |
| pERC Reconsideration Meeting | August 16, 2012 |
| Final Recommendation Issued | August 30, 2012 |
| Notification to Implement Issued | September 17, 2012 |
| Therapeutic Area | Pancreatic Neuroendocrine Tumour |
| Recommendation Type | Reimburse with clinical criteria and/or conditions |
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
